Kiyean Nam
Songnam, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Sensitizing tumor response to topoisomerase I antibody drug conjugate by selective CDK7 inhibition.
Journal: bioRxiv : the preprint server for biology
Published: December 08, 2025
Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond.
Journal: American journal of respiratory and critical care medicine
Published: March 21, 2025
The role of cytochrome bc1 inhibitors in future tuberculosis treatment regimens.
Journal: Nature communications
Published: November 04, 2024
An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity.
Journal: Pharmaceutics
Published: December 19, 2023
Novel modeling approach integrating population pharmacokinetics and interspecies scaling to predict human pharmacokinetics of the new anti-tuberculosis agent telacebec (Q203).
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 03, 2023
Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial.
Journal: Antimicrobial agents and chemotherapy
Published: December 12, 2022
A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment.
Journal: Cancers
Published: September 03, 2022
Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects.
Journal: Antimicrobial agents and chemotherapy
Published: October 25, 2021
Telacebec (Q203), a New Antituberculosis Agent.
Journal: The New England journal of medicine
Published: March 27, 2020
Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents.
Journal: European journal of medicinal chemistry
Published: March 16, 2017
Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203.
Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203.
Journal: European journal of medicinal chemistry
Published: July 15, 2016
Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.
Journal: Journal of medicinal chemistry
Published: May 30, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026